EJMK Ventures LLC Makes New $1.62 Million Investment in Astrazeneca Plc $AZN

EJMK Ventures LLC acquired a new stake in Astrazeneca Plc (NYSE:AZN) in the 4th quarter, Holdings Channel reports. The institutional investor acquired 9,249 shares of the company’s stock, valued at approximately $1,623,000. Astrazeneca accounts for about 1.0% of EJMK Ventures LLC’s portfolio, making the stock its 22nd largest position.

A number of other institutional investors have also recently made changes to their positions in AZN. TD Asset Management Inc lifted its stake in Astrazeneca by 20.0% in the third quarter. TD Asset Management Inc now owns 1,089,612 shares of the company’s stock worth $83,595,000 after acquiring an additional 181,273 shares during the period. AMG National Trust Bank increased its position in Astrazeneca by 20.4% during the 3rd quarter. AMG National Trust Bank now owns 42,983 shares of the company’s stock valued at $3,298,000 after purchasing an additional 7,289 shares during the period. US Bancorp DE raised its holdings in Astrazeneca by 6.6% in the 3rd quarter. US Bancorp DE now owns 242,181 shares of the company’s stock worth $18,581,000 after purchasing an additional 15,065 shares in the last quarter. Natixis Advisors LLC lifted its position in shares of Astrazeneca by 14.3% in the 3rd quarter. Natixis Advisors LLC now owns 2,100,390 shares of the company’s stock worth $161,142,000 after purchasing an additional 262,465 shares during the period. Finally, Bleakley Financial Group LLC boosted its stake in shares of Astrazeneca by 8.4% during the 3rd quarter. Bleakley Financial Group LLC now owns 79,983 shares of the company’s stock valued at $6,136,000 after purchasing an additional 6,172 shares in the last quarter. Hedge funds and other institutional investors own 20.35% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on AZN shares. Barclays reissued a “buy” rating on shares of Astrazeneca in a research note on Monday, June 1st. Morgan Stanley restated an “overweight” rating on shares of Astrazeneca in a research note on Wednesday, April 8th. DZ Bank upgraded Astrazeneca from a “neutral” rating to a “buy” rating in a research report on Wednesday, April 29th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Astrazeneca in a research note on Tuesday, June 9th. Finally, JPMorgan Chase & Co. reissued a “buy” rating on shares of Astrazeneca in a research report on Tuesday, June 9th. Twelve equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Astrazeneca has a consensus rating of “Moderate Buy” and an average target price of $205.33.

Astrazeneca Trading Down 0.0%

Shares of Astrazeneca stock opened at $174.87 on Friday. The company’s fifty day simple moving average is $186.62 and its 200-day simple moving average is $186.27. The stock has a market capitalization of $271.20 billion, a PE ratio of 26.26, a P/E/G ratio of 1.52 and a beta of 0.25. Astrazeneca Plc has a 1-year low of $137.23 and a 1-year high of $212.71. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.91 and a quick ratio of 0.71.

Astrazeneca (NYSE:AZN) last posted its quarterly earnings data on Wednesday, April 29th. The company reported $2.58 EPS for the quarter, topping the consensus estimate of $2.52 by $0.06. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%.The firm had revenue of $15.29 billion during the quarter, compared to analyst estimates of $14.93 billion. As a group, equities analysts anticipate that Astrazeneca Plc will post 9.39 earnings per share for the current year.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.